The 2nd International Electronic Conference on Vaccines
Thank you for attending to IECV2024!
We invite you to contribute a full manuscript to the conference's Special Issue "Challenges to Developing New Vaccines and Improving Existing Platforms", published in Vaccines (Impact Factor 5.2) with a 10% discount.
Click HERE for abstract book.
Click HERE for poster gallery.
The winners for the Best Presentation Awards and Best Poster Awards can be checked out here.
the chair
There are currently major challenges to developing new vaccines and improving existing platforms for both infectious diseases and cancer. Novel methods of vaccine delivery for both human and different animal species are required. Advances in vaccine design to give broad protection to mitigate against the mutation of antigens and to provide both good humoral and cellular immunity are a priority. For flaviviruses, particularly dengue, there are major hurdles to producing vaccines, which not only cover all the serotypes but also prevent the induction of antibody-dependent enhancement. Inactivated and subunit vaccines need to be combined with effective long-acting adjuvants to optimise their potential. In all cases, novel assays, in particular omics-based approaches, are necessary to evaluate in-depth and early responses to vaccination.
The IECV 2024 invites researchers from academia, as well as vaccine practitioners, to contribute original findings, novel ideas, scientific concepts, and new technologies and experiences to deal with immunology mechanisms, animal models for immunologic diseases, viral immunology, immunopathogenesis, vaccine development and efficacy evaluation, immune responses to vaccines, vaccine technology, vaccine vectors, adjuvants, and immunomodulators, with reference to the following topics:
Cancer vaccines, immunotherapy, and immunoprevention;
Challenges of developing a dengue vaccine;
Vaccine adjuvants;
mRNA vaccines;
Advancement in vaccine design for broad protection;
Novel assays for evaluating responses to vaccination.
The conference will be held entirely online, allowing people from all around the world to participate without any concerns about travel or related expenses. An electronic conference offers a platform for quick and direct exchanges of the latest research findings and innovative ideas.
The vaccine scientific community's support and enthusiasm are greatly appreciated, as you play a crucial role in ensuring the success of this 2nd edition of IECV. Your contribution will pave the way for many more successful editions in the future.
Kind regards,
Professor Sara Louise Cosby
School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK
Virology, Veterinary Sciences Division, Agri-Food and Biosciences Institute, UK
Meet the Event Chair
Important Dates
- Abstract submission deadlineSep 16, 2024
- Abstract acceptance notificationSep 30, 2024
- Registration end dateNov 24, 2024
Meet Our Speakers
Prof. Eva Sevick
University of Texas Health Science Center’s Institute of Molecular Medicine (IMM) , USA;
Prof. Eva M. Sevick, Ph.D. is At the IMM she leads the National Cancer Institute Center for Translational Research which focuses upon the development and validation of new imaging instrumentation, algorithms, and imaging agents and their clinical translation. She has pioneered the development of near-infrared fluorescence optical imaging and tomography for molecular imaging and currently has two clinical trials underway at the University of Texas Health Science Center and Memorial Hermann Hospital that employ the technology for novel diagnostic imaging of lymphatic function. Her team is active in preclinical, small animal imaging with nuclear and optical techniques and is pioneering diagnostic imaging for nodal staging in cancer. Dr. Sevick received her Ph.D. in Chemical Engineering at Carnegie Mellon University with Rakesh Jain, her post-doctoral training in Biochemistry and Biophysics at the University of Pennsylvania with Britton Chance, and has served on the faculties at Vanderbilt, Purdue, Texas A&M as well as Baylor College of Medicine. She is past recipient of the National Science Foundation Young Investigator Award, the National Institutes of Health Research Career Award, and the American Cancer Society Research Scholar Award and has served as an appointed member of the Biomedical Imaging Study section, associate editor of the IEEE Transactions of Medical Imaging, and officer of the Society of Molecular Imaging.
Prof. Dr. Martin F. Bachmann
1. Department of Immunology, University of Bern, Bern, Switzerland, 2. Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK;
Martin Bachmann studied Cell Biology at the ETH Zürich. In 1995, he earned his PhD Immunology from the ETH Zürich in Switzerland under the supervision of Prof. Zinkernagel in Zürich followed by a Post-Doc at the laboratory of Prof. Ohashi in Canada. After working as a member at the Basel Institute for Immunology and running research at a Biotech company for 10 years, Martin Bachmann became a faculty member and full professor at the University of Bern. Martin is currently professor at the University of Bern and University of Oxford.
Dr. Byron Martina
Erasmus MC, Rotterdam, Netherlands;
Dr. Antonio Di Lorenzo
Interdisciplinary Department of Medicine, University of Study of Bari, Bari, Italy;
Dr. Yee Joo Tan
Principal Investigator Collaborative Anti-Viral Research group (CAVR), Institute of Molecular and Cell Biology (IMCB), Proteos, Singapore;
- S1. Cancer Vaccines, Immunotherapy, and Immunoprevention
- S2. Challenges of Developing a Dengue Vaccine
- S3. Vaccine Adjuvants
- S4. mRNA Vaccines
- S5. Advancement in Vaccine Design for Broad Protection
Sponsors and Partners
Organizer
Media partner
DAY 1
Session 5. Advancement in Vaccine Design for Broad Protection
Session 1. Cancer Vaccines, Immunotherapy, and Immunoprevention
Session 5. Advancement in Vaccine Design for Broad Protection
DAY 2
Session 3. Vaccine Adjuvants
S6. Novel Assays for Evaluating Responses to Vaccination
DAY 3
S4. mRNA Vaccines
Session 2. Challenges of Developing a Dengue Vaccine
Ms. Amy Chen
Ms. Cynthia Wang
Ms. Theodora Felegean
Email: iecv2024@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.